cystic fibrosis phase II trial
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat ®, a handheld inhaler
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cystic Fibrosis | Research